NCT02359968 2026-03-18
PROTECT
Centre Oscar Lambret
Phase 2 Completed
Clinical Trials
5,987 trialsNCT03793361 2026-03-18
EREMISS
Centre Oscar Lambret
Phase 2 Completed
NCT04251949 2026-03-18
MuciLight
Centre Oscar Lambret
Phase 2 Completed
NCT01612351 2026-03-17
Multimodality Risk Adapted Tx Including Induction Chemo for SCCHN Amenable to Transoral Surgery
UNC Lineberger Comprehensive Cancer Center
Phase 2 Completed
NCT02818920 2026-03-17
TOP 1501
Duke University
Phase 2 Completed
NCT03462342 2026-03-17
CAPRI
University of Pennsylvania
Phase 2 Completed
NCT00417495 2026-03-16
IGASSU
Centre Oscar Lambret
Phase 2 Completed
NCT00420563 2026-03-16
PAL-ANGI
Centre Oscar Lambret
Phase 2 Completed
NCT01303094 2026-03-16
T-DIS
Centre Oscar Lambret
Phase 2 Completed
NCT01658462 2026-03-16
VAROCE
Centre Oscar Lambret
Phase 2 Completed
NCT02437656 2026-03-16
METCAP
Centre Oscar Lambret
Phase 2 Completed
NCT02439034 2026-03-16
KETOCOL
Centre Oscar Lambret
Phase 2 Completed
NCT03643510 2026-03-16
Evaluating Cancer Response to Treatment With Abemaciclib and Fulvestrant in Women With Recurrent Endometrial Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT04703686 2026-03-16
Treatment by a Bispecific CD3xCD20 Antibody for Relapse/Refractory Lymphomas After CAR T-cells Therapy
The Lymphoma Academic Research Organisation
Phase 2 Completed
NCT05340413 2026-03-16
RADIOLA
SOLTI Breast Cancer Research Group
Phase 2 Completed
NCT01165346 2026-03-13
CKNO-HEP
Centre Oscar Lambret
Phase 2 Completed
NCT01303497 2026-03-13
ANGIO-TAX+
Centre Oscar Lambret
Phase 2 Completed
NCT01596816 2026-03-13
CKNO-PRO
Centre Oscar Lambret
Phase 2 Completed
NCT01900743 2026-03-13
REGO-SARC
Centre Oscar Lambret
Phase 2 Completed
NCT02648282 2026-03-13
Study With CY, Pembrolizumab, GVAX Pancreas Vaccine, and SBRT in Patients With Locally Advanced Pancreatic Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
NCT03475186 2026-03-13
Testing Ramipril to Prevent Memory Loss in People With Glioblastoma
Wake Forest University Health Sciences
Phase 2 Completed
NCT04301778 2026-03-13
Durvalumab and SNDX-6532 Following Chemo or Radio-Embolization for Patients With Intrahepatic Cholangiocarcinoma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
NCT07466758 2026-03-12
Personalized Pharmaconutrition Therapy for Myosteatosis, Sarcopenia, and Prognosis in Gastric Cancer Patients
Biruni University
Phase 2 Completed
NCT02829918 2026-03-11
Study of Nivolumab in Patients With Advanced Refractory Biliary Tract Cancers
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Completed
NCT03313804 2026-03-11
Priming Immunotherapy in Advanced Disease With Radiation
University of Kentucky
Phase 2 Completed
NCT04044937 2026-03-11
UC-GlioFET
University of California, San Francisco
Phase 2 Completed
NCT02867956 2026-03-10
Apatinib and Etoposide in Patients With Platinum Resistant or Refractory Ovarian Cancer
Sun Yat-sen University
Phase 2 Completed
NCT03226418 2026-03-10
Geriatric Assessment & Genetic Profiling to Personalize Therapy in Older Adults With Acute Myeloid Leukemia
University of Nebraska
Phase 2 Completed
NCT03446157 2026-03-10
Palbociclib and Cetuximab in Metastatic Colorectal Cancer
UNC Lineberger Comprehensive Cancer Center
Phase 2 Completed
NCT03458260 2026-03-10
Study of Pixantrone in CD20+ Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma
The Lymphoma Academic Research Organisation
Phase 2 Completed
NCT03523702 2026-03-10
SPRINT
Albert Einstein College of Medicine
Phase 2 Completed
NCT04341883 2026-03-10
Study of Anti-PD-1 Combined With Albumin-Bound Paclitaxel in Patients With Recurrent Cervical Cancer
Sun Yat-sen University
Phase 2 Completed
NCT07460596 2026-03-10
Concentrated Complex Plant Dietary Elements for Chemotherapy-Induced Diarrhea
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Completed
NCT03477539 2026-03-09
Daratumumab in Treating Transplant-Eligible Patients With Multiple Myeloma
Mayo Clinic
Phase 2 Completed
NCT04965597 2026-03-09
Treosulfan-Based Conditioning Regimen Before a Blood or Bone Marrow Transplant for the Treatment of Bone Marrow Failure Diseases (BMT CTN 1904)
Fred Hutchinson Cancer Center
Phase 2 Completed
NCT00160979 2026-03-06
Transrectal Tumour Oxygen - US Army
University Health Network, Toronto
Phase 2 Completed
NCT01616875 2026-03-06
Bristol Bladder Trial
University Hospitals Bristol and Weston NHS Foundation Trust
Phase 2 Completed
NCT01761929 2026-03-06
5fr SBRT
University Health Network, Toronto
Phase 2 Completed
NCT02047474 2026-03-06
Combination Chemotherapy Before and After Surgery in Treating Patients With Localized Pancreatic Cancer
Yale University
Phase 2 Completed
NCT03322267 2026-03-06
Adjuvant Pembrolizumab for Patients With Locally Advanced Esophageal Squamous Cell Carcinoma at High Risk of Recurrence
National Taiwan University Hospital
Phase 2 Completed
NCT03361306 2026-03-06
LCI-HEM-MYE-CRD-002: Carfilzomib-Revlimid-Dexamethasone-Elotuzumab in Relapsed/Refractory Multiple Myeloma
Wake Forest University Health Sciences
Phase 2 Completed
NCT04705818 2026-03-06
CAIRE
Institut Bergonié
Phase 2 Completed
NCT06820320 2026-03-06
Oral Iohexol in the Management of Chylous Ascites After After Retroperitoneal or Extended Lymphadenectomy
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Completed
NCT05008900 2026-03-05
TOPP
University Health Network, Toronto
Phase 2 Completed
NCT06071052 2026-03-05
DREAM
First Affiliated Hospital, Sun Yat-Sen University
Phase 2 Completed
NCT02286726 2026-03-04
CPX-351 in Treating Patients With Newly Diagnosed, High-Risk Acute Myeloid Leukemia
M.D. Anderson Cancer Center
Phase 2 Completed
NCT04288687 2026-03-04
A Trial of Niraparib in Platinum-Sensitive Castration-Resistant Prostate Cancer With DNA Repair Defects
Abramson Cancer Center at Penn Medicine
Phase 2 Completed
NCT01409200 2026-03-03
Antiandrogen Therapy With or Without Axitinib Before Surgery in Treating Patients With Previously Untreated Prostate Cancer With Known or Suspected Lymph Node Metastasis
M.D. Anderson Cancer Center
Phase 2 Completed
NCT01560416 2026-03-03
Fulvestrant With or Without Ganetespib in HR+ Breast Cancer
Dana-Farber Cancer Institute
Phase 2 Completed
NCT03519412 2026-03-03
ARETHUSA
IFOM ETS - The AIRC Institute of Molecular Oncology
Phase 2 Completed